
Last updated: 2026-09-05 22:01:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Kura Oncology, Inc. (KURA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13.26, with a market capitalization of $1.17B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.36 to $13.90. This page covers its latest market performance, valuation, price trends and company information.
$1.17B | |
$12.94 | |
$43.00 | |
$2.50 | |
$13.15 | |
1.10M | |
-- | |
-- | |
$13.90 | |
$7.36 | |
-- | |
-- |
Kura Oncology, Inc. (KURA) last closed at $13.15 as of 2026-09-04 23:31:00, unchanged from the previous close of $13.15.
During the latest regular trading session, KURA traded between $2.50 and $43.00, with a volume of 1.10M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Kura Oncology, Inc. (KURA) moved from $12.71 to $13.26, representing a gain of 4.33% ($0.55).
The stock traded between $12.93 and $13.28 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.76 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.2%
KURA is currently trading at $13.26, placing it 90.2% of the way from its 52-week low of $7.36 to its 52-week high of $13.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 260 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kura Oncology, Inc. (KURA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.